MedTrace Logo

Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH

NCT01406704 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2011-08-19

No results posted yet for this study

Summary

This study is to evaluate the effects of Rosiglitazone, insulin sensitizer and alpha-lipoic acid, antioxidant on patients with pathologically proved NASH (non-alcoholic steato-hepatitis).

Conditions

  • NASH (Non-alcoholic Steato-hepatitis)

Interventions

DRUG

Rosiglitazone

Rosiglitazone (8 mg/day)

DRUG

alpha-lipoic acid

alpha-lipoic acid (1800 mg/day)

DRUG

Rosiglitazone/alpha-lipoic acid

combination of Rosiglitazone (8 mg/day) and Thioctic acid (1800 mg/day)

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Seoul St. Mary's Hospital

    lead OTHER

Principal Investigators

  • Kun Ho Yoon · Seoul St. Mary's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-31
Primary Completion
2010-12-31
Completion
2013-12-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01406704 on ClinicalTrials.gov